Affimed N.V. (AFMD)

Trade AFMD now with
3/29/2023 6:35:54 AM Affimed Doses First Patient In First-in-Human Study Of AFM28 For Patients With Relapsed / Refractory CD123-Positive AML
6/1/2022 6:43:41 AM Affimed Q1 Net Loss EUR 16.7 Mln Or EUR 0.14/Shr Vs Income Of EUR 1.4 Mln Or EUR 0.01/Shr Last Year
1/6/2022 6:36:21 AM Affimed Completes Enrollment Of REDIRECT Study; Sees Topline Clinical Readout In 2H 2022
12/8/2021 6:38:04 AM Affimed Initiates Patient Recruitment For Phase 1/2a Trial Of Innate Cell Engager AFM24 With Roche’s Atezolizumab
7/1/2021 6:37:37 AM Affimed Q1 Net Income EUR 1.4 Mln Or EUR 0.01/Shr Vs Loss Of EUR 8.3 Mln Or EUR 0.11/Shr Last Year
3/10/2021 6:37:04 AM Affimed To Continue Enrollment In REDIRECT Trial For Patients With Relapsed Or Refractory CD30-positive PTCL
1/13/2021 6:27:42 AM Affimed Prices $100 Mln Public Offering Of Common Shares